| David R Tomazic, DO | |
|
100 Dundaff St, Forest City, PA 18421-1317 | |
| (570) 785-3194 | |
| Not Available |
| Full Name | David R Tomazic |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 46 Years |
| Location | 100 Dundaff St, Forest City, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912992751 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QG0300X | Family Medicine - Geriatric Medicine | 0S004178L (Pennsylvania) | Secondary |
| 207Q00000X | Family Medicine | 0S004178L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Interim Healthcare Services Of Ne Pa, Inc. | Blakely, PA | Home health agency |
| Personal Home Healthcare And Hospice | Dunmore, PA | Home health agency |
| Home Health Care Professionals And Hospice | Eynon, PA | Hospice |
| Wayne Memorial Hospital | Honesdale, PA | Hospital |
| Geisinger-community Medical Center | Scranton, PA | Hospital |
| Forest City Nursing And Rehab Center | Forest city, PA | Nursing home |
| Wayne Woodlands Manor | Waymart, PA | Nursing home |
| Carbondale Nursing And Rehabilitation Center | Carbondale, PA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wayne Memorial Community Health Centers | 3072598937 | 18 |
News Archive
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug's bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.
Nordic Naturals Professional Exclusive Division announces Prenatal DHA, a product developed especially for pregnant women to ensure adequate DHA, an important omega-3 essential fatty acid and a vital nutrient for the new mother and developing baby.
Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.
A home-based palliative care (HBPC) program for individuals with advanced illnesses was associated with a $12,000 reduction in the mean total cost of care per person, fewer hospital admissions and emergency room visits, and greater use of hospice during the final three months of life, as reported in a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 6 days ago
| Entity Name | Wayne Memorial Community Health Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952395121 PECOS PAC ID: 3072598937 Enrollment ID: O20040623001109 |
News Archive
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug's bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.
Nordic Naturals Professional Exclusive Division announces Prenatal DHA, a product developed especially for pregnant women to ensure adequate DHA, an important omega-3 essential fatty acid and a vital nutrient for the new mother and developing baby.
Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.
A home-based palliative care (HBPC) program for individuals with advanced illnesses was associated with a $12,000 reduction in the mean total cost of care per person, fewer hospital admissions and emergency room visits, and greater use of hospice during the final three months of life, as reported in a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David R Tomazic, DO 601 Park St, Honesdale, PA 18431-1445 Ph: (570) 785-3194 | David R Tomazic, DO 100 Dundaff St, Forest City, PA 18421-1317 Ph: (570) 785-3194 |
News Archive
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug's bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.
Nordic Naturals Professional Exclusive Division announces Prenatal DHA, a product developed especially for pregnant women to ensure adequate DHA, an important omega-3 essential fatty acid and a vital nutrient for the new mother and developing baby.
Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.
A home-based palliative care (HBPC) program for individuals with advanced illnesses was associated with a $12,000 reduction in the mean total cost of care per person, fewer hospital admissions and emergency room visits, and greater use of hospice during the final three months of life, as reported in a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 6 days ago